Table 2 Baseline characteristics of study participants for the analysis of chronic pancreatitis.
From: Rheumatoid arthritis and risk of pancreatitis: a nationwide cohort study
Total | RA status | Serological status of RA | |||||
|---|---|---|---|---|---|---|---|
Non-RA | RA | P-value | SPRA | SNRA | p-value | ||
Participants, No | 184,660 | 138,495 | 46,165 | 32,185 | 13,350 | ||
Sex, Male | 41,972 (22.7) | 31,479 (22.7) | 10,493 (22.7) | 7,247 (22.1) | 3,246 (24.3) | < 0.0001 | |
Age | 58.3 ± 9.9 | 58.3 ± 9.9 | 58.3 ± 9.9 | 58.5 ± 9.9 | 57.7 ± 10.0 | < 0.0001 | |
40–59 | 104,852 (56.8) | 78,639 (56.8) | 26,213 (56.8) | 18,316 (55.8) | 7,897 (59.2) | ||
≥ 60 | 79,808 (43.2) | 59,856 (43.2) | 19,952 (43.2) | 14,499 (44.2) | 5,453 (40.9) | ||
Income | |||||||
< 25% | 41,383 (22.4) | 31,011 (22.4) | 10,372 (22.5) | 0.046 | 7,399 (22.6) | 2,973 (22.3) | 0.0002 |
Smoking status | < 0.0001 | < 0.0001 | |||||
Never | 151,098 (81.8) | 113,985 (82.3) | 37,113 (80.4) | 26,409 (80.5) | 10,704 (80.2) | ||
Former | 16,670 (9.03) | 12,090 (8.7) | 4,580 (9.9) | 3,036 (9.3) | 1,544 (11.6) | ||
Current | 16,892 (9.2) | 12,420 (9.0) | 4,472 (9.7) | 3,370 (10.3) | 1,102 (8.3) | ||
Alcohol consumption | < 0.0001 | < 0.0001 | |||||
None | 138,681 (75.1) | 102,289 (73.9) | 36,392 (78.8) | 26,031 (79.3) | 10,361 (77.6) | ||
< 30 g/day | 45,979 (24.9) | 36,206 (26.1) | 9,773 (21.2) | 6,784 (20.7) | 2,989 (22.4) | ||
Physical activity | |||||||
Regular | 37,273 (20.2) | 28,825 (20.8) | 8,448 (18.3) | < 0.0001 | 5,850 (17.8) | 2,598 (19.5) | < 0.0001 |
Body mass index | < 0.0001 | < 0.0001 | |||||
< 18.5 | 5,363 (2.9) | 3,594 (2.6) | 1,769 (3.8) | 1,331 (4.1) | 438 (3.3) | ||
18.5–23 | 73,021 (39.5) | 53,727 (38.8) | 19,294 (41.8) | 14,027 (42.8) | 5,267 (39.5) | ||
23–25 | 46,110 (25.0) | 34,841 (25.2) | 11,269 (24.4) | 8,003 (24.4) | 3,266 (24.5) | ||
25–30 | 53,163 (28.8) | 40,917 (29.5) | 12,246 (26.5) | 8,454 (25.8) | 3,792 (28.4) | ||
≥ 30 | 7,003 (3.8) | 5,416 (3.9) | 1,587 (3.4) | 1,000 (3.1) | 587 (4.4) | ||
Diabetes mellitus | 23,018 (12.5) | 17,311 (12.5) | 5,707 (12.4) | 0.4396 | 3,949 (12.0) | 1,758 (13.2) | < 0.0001 |
Hypertension | 69,670 (37.7) | 51,433 (37.1) | 18,237 (39.5) | < 0.0001 | 12,519 (38.2) | 5,718 (42.8) | < 0.0001 |
Dyslipidemia | 60,416 (32.7) | 45,209 (32.6) | 15,207 (33.0) | 0.2381 | 10,317 (31.4) | 4,890 (36.6) | < 0.0001 |
Chronic kidney disease | 12,858 (7.0) | 9,150 (6.6) | 3,708 (8.0) | 2,473 (7.5) | 1,235 (9.3) | ||
Lipid profile | |||||||
*TG | 106.3 (106.0-106.6) | 107.2 (107.0-107.8) | 103.4 (102.9-103.9) | < 0.0001 | 102.0 (101.4-102.5) | 107.1 (106.2–108.0) | < 0.0001 |
Chronic pancreatitis | 174 (0.09) | 124 (0.09) | 50 (0.11) | 0.2549 | 39 (0.12) | 11(0.08) | 0.2803 |
F/U duration | |||||||
Mean ± SD | 5.6 ± 2.3 | 5.6 ± 2.25 | 5.5 ± 2.3 | < 0.0001 | 5.5 ± 2.3 | 5.5 ± 2.2 | 0.1486 |
Median (Q1-Q3) | 5.5 (3.7–7.5) | 5.5 (3.7–7.5) | 5.4 (3.6–7.4) | < 0.0001 | 5.4 (3.6–7.5) | 5.4 (3.6–7.3) | 0.0378 |
